National leader in home health and hospice care to extend AI-enabled speech, language, and cognitive therapy initiative across its network…
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused…
Former Chief Business Leader of Philips’ multi-billion-dollar Precision Diagnosis division and member of Philips’ Executive CommitteeEnd-to-end responsibility for Philip’s CT,…
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination…
Contributing Funding and a Significant Additional Tool to Combat PTSD and TBIJACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) --…
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the…
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of…
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the…
Milestone Results in $8 Million Payment to C4 Therapeutics WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc.…
Trisha Pfluger, M.S., PMP, Chief Scientific Officer, and Nicholas Totagrande, CEO, Juno Biomedical, Inc. talk medical advancement, AI, and next…